You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 expression

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial in Beijing, Langfang (RC48-ADC)

Recruiting
  • Metastatic Breast Cancer
  • Beijing, Beijing, China
  • +2 more
Apr 8, 2022

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

Breast Cancer Female Trial in Tomsk (99mTc-ADAPT6, 99mTc-DARPinG3)

Recruiting
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Tomsk NRMC
May 12, 2022

HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive

Recruiting
  • HER2-positive Breast Cancer
  • Acquisition of blood samples and tumour tissue samples (biopsies)
  • Brighton, United Kingdom
  • +1 more
Nov 9, 2022

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

HER2-positive Breast Cancer Trial in Uppsala (ABY-PET)

Recruiting
  • HER2-positive Breast Cancer
  • ABY-PET
  • Uppsala, Sweden
    Section for Clinical Research & Development Unit
Sep 28, 2021

Cancers With HER2 Expression Trial in United Kingdom, United States (BAY2701439)

Recruiting
  • Cancers With HER2 Expression
  • Baltimore, Maryland
  • +5 more
Jan 18, 2023

Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

Recruiting
  • Breast Cancer
  • Chidamide Plus Toripalimab Plus Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 19, 2023

Primary Breast Cancer Trial in Tomsk (SPECT)

Completed
  • Primary Breast Cancer
  • Tomsk, Russian Federation
    TomskNRMC
Oct 4, 2021

Breast Tumors, Gastric Tumor, Solid Tumors Trial in Australia, United States (ARX788)

Recruiting
  • Breast Neoplasms
  • +2 more
  • Los Angeles, California
  • +8 more
Feb 25, 2022

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

Breast Cancer, HER2-positive Breast Cancer Trial (Recombinant humanized anti-HER2 mAb-MMAE coupling agent (RC48-ADC))

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)
  • (no location specified)
Nov 14, 2021

Breast Tumors, Breast Cancer, Adenocarcinomas Trial run by the NCI (AdHER2/neu DC Vaccine)

Completed
Has Results
  • Breast Neoplasms
  • +3 more
  • Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 12, 2022

Solid Tumors, Adult Trial in Dallas, Hangzhou (HF158K1 /Arm 2 mg/m², HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m²)

Not yet recruiting
  • Solid Tumors, Adult
  • HF158K1 /Arm 2 mg/m²
  • +5 more
  • Dallas, Texas
  • +2 more
May 6, 2023

Advanced Gastroesophageal Adenocarcinoma Trial in Beijing (RC48-ADC, S-1)

Recruiting
  • Advanced Gastroesophageal Adenocarcinoma
  • Beijing, China
  • +2 more
Sep 14, 2022

Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas Trial in Brussels (68GaNOTA-Anti-HER2 VHH1)

Recruiting
  • Metastatic Breast Carcinoma
  • +13 more
  • 68GaNOTA-Anti-HER2 VHH1
  • Brussels, Brussel, Belgium
    Uz Brussel
Dec 17, 2021

Gynecological Malignancy Trial in Beijing (RC48-ADC)

Recruiting
  • Gynecological Malignancy
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences Cancer Hospital
Jan 6, 2022

Breast Cancer, Locally Advanced or Metastatic Solid Tumor Trial in Guangdong (BL-M07D1)

Not yet recruiting
  • Breast Cancer
  • Locally Advanced or Metastatic Solid Tumor
  • Guangdong, Guangzhou, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2022

Advanced Breast Cancer Trial in China (RC48-ADC 1.5 mg/kg (HER2 Positive), RC48-ADC 2.0 mg/kg (HER2 Positive), RC48-ADC 2.5

Active, not recruiting
  • Advanced Breast Cancer
  • RC48-ADC 1.5 mg/kg (HER2 Positive)
  • +3 more
  • Beijing, Beijing, China
  • +3 more
Jan 7, 2022

Breast Cancer Metastatic Trial in Worldwide (MCLA-128, Trastuzumab, Vinorelbine)

Active, not recruiting
  • Breast Cancer Metastatic
  • Los Angeles, California
  • +24 more
Aug 10, 2022

IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung

Completed
  • Non Small Cell Lung Cancer
  • Protein expression by immunohistochemistry and immunofluorescence
  • Rozzano, Milan, Italy
    Istituto Clinco Humanitas
Sep 8, 2022

Real-World Data of Clinicopathological Characteristics and

Recruiting
  • Early Breast Cancer
  • +2 more
    • Barcelona, Spain
    • +9 more
    Jan 18, 2023

    99mTc-ADAPT6-based HER2 Imaging in Breast Cancer

    Completed
    • Breast Cancer
    • SPECT
    • Tomsk, Russian Federation
      TomskNRMC
    Mar 30, 2021

    HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor Trial in Seattle

    Active, not recruiting
    • HER2-positive Breast Cancer
    • +8 more
    • pNGVL3-hICD vaccine
    • +6 more
    • Seattle, Washington
      Fred Hutchinson Cancer Research Center/University of Washington
    Nov 1, 2022

    Breast Cancer Trial (Diagnostic microprobe (inPROBE) medical device)

    Recruiting
    • Breast Cancer
    • Diagnostic microprobe (inPROBE) medical device
    • Kraków, Poland
    • +1 more
    Nov 2, 2022